New Therapeutic Targets in Rheumatoid Arthritis

  • Paul-Peter Tak

Part of the Progress in Inflammation Research book series (PIR)

Table of contents

  1. Front Matter
    Pages i-xii
  2. Edward M. Vital, Shouvik Dass, Paul Emery
    Pages 1-26
  3. Eric M. Ruderman, Richard M. Pope
    Pages 27-43
  4. Wim B. van den Berg, Leo A. B. Joosten, Fons A. J. van de Loo
    Pages 59-74
  5. Jagtar Nijar Singh, Iain B. McInnes
    Pages 75-88
  6. Pierre Miossec, Ling Toh, Saloua Zrioual
    Pages 89-101
  7. Charles A. Dinarello
    Pages 103-127
  8. Zoltán Szekanecz, Alisa E. Koch
    Pages 129-153
  9. Jean-Marc Waldburger, Gary S. Firestein
    Pages 155-180
  10. Theresa C. Barnes, Robert J. Moots
    Pages 181-191
  11. Lars C. Huber, Astrid Jüngel, Steffen Gay
    Pages 193-206
  12. Edward C. Keystone
    Pages 207-220
  13. Back Matter
    Pages 221-228

About this book


The volume focuses on therapeutic targets that were identified after TNF blockade and that have recently been registered or are currently under development for the treatment of rheumatoid arthritis. Each chapter discusses the biological rationale in great detail, including in vitro work and work in animal models, and where appropriate, results from clinical trials.

The book is written by an international authorship of experts in this field. It is of interest to rheumatologists, immunologists, internists, investigators in immunology and rheumatology as well as the pharmaceutical industry.


Arthritis Chemokine Drug Target Interleukine Rheumatology antibody cell clinical trial diseases drug immunobiology immunology inflammation research rheumatoid arthritis

Editors and affiliations

  • Paul-Peter Tak
    • 1
  1. 1.Division of Clinical Immunology and Rheumatology EULAR & FOCIS Center of Excellence Academic Medical CenterUniversity of AmsterdamAZ AmsterdamThe Netherlands

Bibliographic information

Industry Sectors
Health & Hospitals
Internal Medicine & Dermatology